Skip to main content
Advanced Technical IVT

tumor genomic complexity

The overall burden of genetic alterations in a tumor, including point mutations, structural variants, and chromosomal aberrations, which may influence therapeutic response and prognosis.

Full Definition

Tumor genomic complexity refers to the total accumulation of genetic alterations within a cancer genome, encompassing single nucleotide variants, insertions and deletions, copy number alterations, structural rearrangements, and chromosomal instability. This metric provides insight into the underlying mutational processes driving cancer development and may correlate with clinical outcomes. High genomic complexity is often associated with defective DNA repair mechanisms, advanced disease stage, and potential sensitivity to certain therapeutic approaches like immunotherapy or DNA damage response inhibitors. Conversely, tumors with low complexity may harbor specific driver alterations amenable to targeted therapy. Genomic complexity assessment helps classify tumors into distinct molecular subtypes and can inform treatment selection strategies. Various computational metrics are used to quantify complexity, including total mutation count, structural variation burden, and chromosomal instability scores.

Usage

Usage note: Broader concept than TMB; encompasses all types of genomic alterations, not just point mutations.

In Context

  • "High tumor genomic complexity suggested defective DNA repair mechanisms and potential immunotherapy sensitivity." — Genomic analysis interpretation
  • "The tumor showed low genomic complexity with few driver mutations amenable to targeted therapy." — Molecular profiling summary

Also known as

genomic instability mutational burden

Contrasted with

genomic stability low complexity

Don't confuse with

tumor mutational burden chromosomal instability

Editors from these organisations have used our services since 1998

Reuters BBC Oxford University Press Penguin Random House Springer Microsoft Suncor Energy United Nations Fisher Investments IBM The Home Depot KODAK CHEVRON